LENSAR (LNSR) Competitors $11.61 -0.37 (-3.09%) Closing price 10/15/2025 04:00 PM EasternExtended Trading$11.64 +0.03 (+0.22%) As of 10/15/2025 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LNSR vs. BVS, ZIMV, AVNS, KIDS, CBLL, SMLR, TMCI, DCTH, CARL, and NPCEShould you be buying LENSAR stock or one of its competitors? The main competitors of LENSAR include Bioventus (BVS), ZimVie (ZIMV), Avanos Medical (AVNS), OrthoPediatrics (KIDS), CeriBell (CBLL), Semler Scientific (SMLR), Treace Medical Concepts (TMCI), Delcath Systems (DCTH), Carlsmed (CARL), and NeuroPace (NPCE). These companies are all part of the "medical equipment" industry. LENSAR vs. Its Competitors Bioventus ZimVie Avanos Medical OrthoPediatrics CeriBell Semler Scientific Treace Medical Concepts Delcath Systems Carlsmed NeuroPace LENSAR (NASDAQ:LNSR) and Bioventus (NYSE:BVS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, dividends, valuation and profitability. Do institutionals and insiders have more ownership in LNSR or BVS? 40.2% of LENSAR shares are held by institutional investors. Comparatively, 62.9% of Bioventus shares are held by institutional investors. 38.5% of LENSAR shares are held by insiders. Comparatively, 33.0% of Bioventus shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media refer more to LNSR or BVS? In the previous week, LENSAR had 4 more articles in the media than Bioventus. MarketBeat recorded 4 mentions for LENSAR and 0 mentions for Bioventus. LENSAR's average media sentiment score of 1.08 beat Bioventus' score of 0.00 indicating that LENSAR is being referred to more favorably in the media. Company Overall Sentiment LENSAR Positive Bioventus Neutral Is LNSR or BVS more profitable? Bioventus has a net margin of -7.11% compared to LENSAR's net margin of -84.49%. Bioventus' return on equity of 15.61% beat LENSAR's return on equity.Company Net Margins Return on Equity Return on Assets LENSAR-84.49% -737.30% -72.60% Bioventus -7.11%15.61%4.01% Which has better valuation and earnings, LNSR or BVS? LENSAR has higher earnings, but lower revenue than Bioventus. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLENSAR$53.49M2.59-$31.40M-$4.21-2.76Bioventus$564.14M1.02-$156.23MN/AN/A Which has more volatility & risk, LNSR or BVS? LENSAR has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500. Comparatively, Bioventus has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500. Do analysts recommend LNSR or BVS? LENSAR currently has a consensus target price of $15.00, suggesting a potential upside of 29.20%. Bioventus has a consensus target price of $13.75, suggesting a potential upside of 98.41%. Given Bioventus' stronger consensus rating and higher possible upside, analysts plainly believe Bioventus is more favorable than LENSAR.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LENSAR 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67Bioventus 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 SummaryBioventus beats LENSAR on 9 of the 15 factors compared between the two stocks. Get LENSAR News Delivered to You Automatically Sign up to receive the latest news and ratings for LNSR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LNSR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LNSR vs. The Competition Export to ExcelMetricLENSARMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$142.98M$7.05B$6.11B$10.46BDividend YieldN/A1.18%5.73%4.77%P/E Ratio-2.7626.2685.3627.36Price / Sales2.5927.41602.77132.73Price / CashN/A21.7037.4661.86Price / Book27.645.2112.426.81Net Income-$31.40M$178.09M$3.32B$276.80M7 Day Performance-3.17%-1.83%0.57%0.42%1 Month Performance-5.99%6.30%10.52%7.86%1 Year Performance105.85%4.63%72.99%41.24% LENSAR Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LNSRLENSAR2.0846 of 5 stars$11.61-3.1%$15.00+29.2%+124.6%$142.98M$53.49M-2.76110Positive NewsBVSBioventus2.4851 of 5 stars$6.73-0.9%$13.75+104.3%-45.6%$555.19M$564.14M-11.011,200ZIMVZimVie1.1701 of 5 stars$18.93+0.0%$17.75-6.2%+27.0%$533.87M$449.75M-27.041,770AVNSAvanos Medical1.5065 of 5 stars$11.47-0.9%N/A-50.2%$530.38M$692.50M-1.142,227Positive NewsAnalyst ForecastKIDSOrthoPediatrics4.6287 of 5 stars$18.14-0.5%$34.14+88.2%-34.0%$454.84M$220.73M-10.13200CBLLCeriBell2.2791 of 5 stars$12.31-2.1%$32.14+161.1%N/A$452.20M$65.44M-4.13N/ASMLRSemler Scientific3.212 of 5 stars$29.73-3.3%$74.25+149.7%-6.8%$442.08M$42.98M12.29120Gap DownTMCITreace Medical Concepts2.3248 of 5 stars$6.18-1.9%$9.83+59.1%+15.0%$390.08M$209.36M-7.82250Analyst ForecastDCTHDelcath Systems2.438 of 5 stars$11.07+2.5%$24.50+121.3%+26.8%$385.49M$70.24M220.4060CARLCarlsmedN/A$13.84-4.4%N/AN/A$367.87M$27.17M0.00100Positive NewsNPCENeuroPace3.5843 of 5 stars$10.79+0.2%$16.60+53.8%+70.0%$356.93M$79.91M-12.85170 Related Companies and Tools Related Companies Bioventus Competitors ZimVie Competitors Avanos Medical Competitors OrthoPediatrics Competitors CeriBell Competitors Semler Scientific Competitors Treace Medical Concepts Competitors Delcath Systems Competitors Carlsmed Competitors NeuroPace Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LNSR) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredShots officially fired…Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the righ...Brownstone Research | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LENSAR, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LENSAR With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
